0001209191-22-047760.txt : 20220826
0001209191-22-047760.hdr.sgml : 20220826
20220826192959
ACCESSION NUMBER: 0001209191-22-047760
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20220824
FILED AS OF DATE: 20220826
DATE AS OF CHANGE: 20220826
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Boyce Sarah
CENTRAL INDEX KEY: 0001629383
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-39321
FILM NUMBER: 221206797
MAIL ADDRESS:
STREET 1: C/O IONIS PHARMACEUTICALS, INC.
STREET 2: 2855 GAZELLE COURT
CITY: CARLSBAD
STATE: CA
ZIP: 92010
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Avidity Biosciences, Inc.
CENTRAL INDEX KEY: 0001599901
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 461336960
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 10578 SCIENCE CENTER DRIVE
STREET 2: SUITE 125
CITY: SAN DIEGO
STATE: CA
ZIP: 92121
BUSINESS PHONE: 858-401-7900
MAIL ADDRESS:
STREET 1: 10578 SCIENCE CENTER DRIVE
STREET 2: SUITE 125
CITY: SAN DIEGO
STATE: CA
ZIP: 92121
FORMER COMPANY:
FORMER CONFORMED NAME: Avidity Biosciences LLC
DATE OF NAME CHANGE: 20161227
FORMER COMPANY:
FORMER CONFORMED NAME: Avidity NanoMedicines LLC
DATE OF NAME CHANGE: 20140211
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2022-08-24
0
0001599901
Avidity Biosciences, Inc.
RNA
0001629383
Boyce Sarah
C/O AVIDITY BIOSCIENCES, INC.
10578 SCIENCE CENTER DRIVE, SUITE 125
SAN DIEGO
CA
92121
1
1
0
0
President and CEO
Common Stock
2022-08-24
4
M
0
35045
1.24
A
35045
D
Common Stock
2022-08-24
4
S
0
35045
22.7971
D
0
D
Common Stock
2022-08-25
4
M
0
14855
1.24
A
14855
D
Common Stock
2022-08-25
4
S
0
14855
23.069
D
0
D
Stock Option (Right to Buy)
1.24
2022-08-24
4
M
0
35045
0.00
D
2029-12-17
Common Stock
35045
1161870
D
Stock Option (Right to Buy)
1.24
2022-08-25
4
M
0
14855
0.00
D
2029-12-17
Common Stock
14855
1147015
D
The option exercise and sale reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person.
The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $22.45 to $23.05.The Reporting Person undertakes to provide the Registrant, any securityholder of the Registrant, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $22.84 to $23.42.The Reporting Person undertakes to provide the Registrant, any securityholder of the Registrant, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
25% of the shares subject to the option vested on October 7, 2020 and 1/48th of the shares subject to the option will vest monthly thereafter.
/s/ John W. Wallen III, Ph.D., J.D., Attorney-in-Fact
2022-08-26